Posted by Michael Wonder on 09 May 2017
Axsome Therapeutics receives FDA fast track designation for AXS-05 for Alzheimer’s disease agitation
8 May 2017 - Axsome Therapeutics received fast track designation from the U.S. FDA for AXS-05 for the treatment of agitation in patients with Alzheimer’s disease.
There are currently no approved treatments for this condition. Axsome previously received Investigational new drug application clearance from the FDA to proceed with a Phase 2/3 trial of AXS-05 in this indication.
